For most manufacturers, a full order book is an uncomplicated good problem. ASML's version is more revealing. Demand for extreme-ultraviolet lithography is now strong enough that the Dutch company is examining how to produce more than 110 EUV machines in 2028. According to JPMorgan analysts who met management, the limiting factor is no longer primarily suppliers. It is the speed at which ASML can assemble the machines.
What the evidence establishes
ASML has said it is nearly sold out of EUV capacity for 2027 and can produce at least 80 systems, with a roughly 30% increase targeted for 2028. JPMorgan said most new orders are already for 2028 delivery. The bank also reported increasing EUV intensity per chip and expects next-generation High-NA adoption to begin in 2028 before becoming more meaningful later. Dutch Business Review recently examined the new NADI-SPRIND effort to add European AI-chip design capability. ASML's capacity question sits at the opposite end of the chain: whether Europe can manufacture enough of the machines needed to turn advanced designs into silicon.
The commercial reading
The strategic implication is easy to miss. ASML's monopoly in EUV is often described as geopolitical leverage, but monopoly also creates responsibility for the pace of an entire industry's expansion. A fab cannot simply buy an equivalent machine from another supplier if Veldhoven is full. That means assembly productivity inside one Dutch company can influence the timing of AI chip capacity in Taiwan, Korea, the United States and Europe. Our conclusion is that ASML's next productivity breakthrough may matter almost as much as its next lithography breakthrough. Increasing output without weakening installation quality or supplier discipline would convert technological dominance into greater industrial throughput.
What to watch next
Watch 2028 order intake, assembly-cycle improvements, High-NA installation times, the Veldhoven expansion and whether ASML formally raises capacity guidance above 110 systems.
How to use this analysis
Technology investment should be tested against deployed capacity, active customers and recurring revenue. Patents, licences, pilots and funding rounds are intermediate evidence. They can be important without proving that a product has reached commercial scale or that an announced facility is operating at its intended load.
Source and verification note
The reporting base for this article is Reuters: ASML examining output above 110 EUV tools in 2028. The link is provided to the source page or release so readers can check the reporting period, definitions and later revisions. Figures are not extended beyond the source's geographic or institutional scope, and forecasts remain labelled as expectations until an official release records the outcome.